MDT

98.76

+1.94%↑

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Open

3.43 1.18

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.37

Max

3.57

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
Winstmarge	-77.289
Werknemers	260
EBITDA	-3.2M -11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+28.79% upside

Dividenden
By Dow Jones
Volgende Winsten	12 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-15M 106M
Vorige openingsprijs	2.25
Vorige sluitingsprijs	3.43

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jan 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 jan 2026, 00:00 UTC

Winsten

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 jan 2026, 23:47 UTC

Marktinformatie

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 jan 2026, 23:39 UTC

Marktinformatie

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 jan 2026, 23:32 UTC

Marktinformatie

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 jan 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 jan 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 jan 2026, 22:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 jan 2026, 22:17 UTC

Marktinformatie

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 jan 2026, 22:09 UTC

Winsten

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 jan 2026, 21:52 UTC

Acquisities, Fusies, Overnames

WuXi XDC Announces Positive Profit Alert for 2025

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Citigroup Acting as Financial Advisor to WuXi XDC

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

14 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jan 2026, 21:49 UTC

Acquisities, Fusies, Overnames

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Makes Cash Offer for BioDlink International

14 jan 2026, 21:13 UTC

Marktinformatie

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 jan 2026, 20:30 UTC

Marktinformatie

Winsten

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 jan 2026, 20:13 UTC

Marktinformatie

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 jan 2026, 20:08 UTC

Marktinformatie

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 jan 2026, 19:33 UTC

Marktinformatie

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 jan 2026, 19:06 UTC

Marktinformatie

Winsten

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

28.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.25 USD 28.79%

Hoogste 5.5 USD

Laagste 3 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.